What Is Lipfendra (Enlicitide), the New Cholesterol Pill?

On July 16, 2026, the FDA approved a new cholesterol-lowering drug called enlicitide, which will be sold under the brand name Lipfendra. It's the first PCSK9 inhibitor you can take as a pill instead of an injection, and it's already generating a lot of questions in my practice. Here's what it is, who it's for, and one caveat I'd want every patient to hear.

How does Lipfendra work?

It's a PCSK9 inhibitor, working on the same cholesterol lowering pathway as drugs such as Repatha, Praluent, and Leqvio. PCSK9 is an enzyme that destroys LDL receptors, and those receptors are what grab LDL out of your bloodstream and clear it. Block PCSK9, and you save more receptors, which means more LDL gets removed and your LDL levels fall. Lipfendra has been shown to lower LDL by 56 to 59%, right in line with the other drugs in this class. What's genuinely new is the format: it's a once-daily tablet, where every other PCSK9 inhibitor has to be injected anywhere from every two weeks to every six months. For people who dislike needles, and that's most people, a pill is a real advance.

Is Lipfendra a statin?

No, and this is worth being clear about. It is not a "stronger statin," and it's nothing like atorvastatin (Lipitor) or rosuvastatin (Crestor). Statins work at the other end of the problem: they block an enzyme called HMG-CoA reductase, so your liver makes less cholesterol and less LDL enters your bloodstream in the first place. A PCSK9 inhibitor helps you clear the LDL that's already there. Statins can lower LDL by as much as 50%, so the two are in the same ballpark on power, just through different mechanisms.

Is it more effective than a statin?

No, and in fact, most studies that have evaluated PCSK9 impact have been done on people already taking statins, with Repatha, or Lipfendra, added on top of another drug. Because statins and PCSK9 inhibitors act on different, complementary steps, using them together can be synergistic: you reduce how much LDL shows up in the bloodstream while also making it easier to remove. People also respond very differently to each. For some, a tiny dose of a statin sends LDL plummeting. Others aren't at goal even on the maximum tolerated statin dose. Some see dramatic drops on a PCSK9 inhibitor alone, while others still need a statin on board too.

One important point - the above paragraph says nothing about outcomes.  We know that statins improve outcomes.  We know that injectable PCSK9 inhibitors improve outcomes.  We don’t know if an oral PCSK9 inhibitor can say the same thing.  After all, Lipfendra doesn’t lower PCSK9 the exact same way as the injectable drugs. We assume it will improve outcomes, but the medical literature is replete with drugs that shared some similarity in effect but ended up needing to be pulled because of some unanticipated negative consequence that led to no outcome benefits or actually worse outcomes.

Should you switch from your statin to Lipfendra?

If your statin is working and you tolerate it, there's no reason to switch. If you're not at your LDL goal despite it, adding Lipfendra is a reasonable next step especially if you prefer to avoid injections. And if you've had genuine side effects from statins, like muscle aches or abnormal liver tests, switching might make sense. As with any medication, new or old, some caution is wise. PCSK9 inhibitors are generally well tolerated, but you never really know how a given drug will affect you until you take it. In terms of side effects, the most common ones reported with Lipfendra were diarrhea and dizziness. Lipfendra does have some inconvenience factors that come along - it needs to be taken on an empty stomach, and you need to wait at least 30 minutes before eating anything.

What does Lipfendra cost?

About $315 for a 30-day supply. That's slightly less than the injectable PCSK9 inhibitors, but it's still roughly 20 times the cost of a month of statins. And FDA approval doesn't guarantee your insurance will pay for it, at least not as a first-line option. Coverage is likely to require prior authorization, and formulary decisions are still being sorted out. As someone who prescribes various cholesterol lowering drugs, I can tell you that an insurer will make me prove that the cholesterol cannot be controlled with low cost generic medications (like statins) before approving a more expensive non-generic drug (like a PCSK9 inhibitor).

What about the new, lower LDL targets?

The latest LDL guidelines define treatment targets that are significantly lower than in the past. This means many more people now qualify for medication, and many more people will need more than one drug to reach the more aggressive goals. The reasoning behind "lower for longer" is sound. After all, bathing our arteries with less LDL day in and day out is a good thing. But we also need to weigh the other side of that coin: bathing our bodies with higher doses of more drugs, for longer. Is that a good trade-off?

The bigger picture

In medicine we are taught to reach for drugs, almost reflexively. High cholesterol? Here's a pill. Still high? Here's another. Often without ever asking why the cholesterol is high in the first place. Some people truly are born with very high PCSK9 levels, a condition called Familial Hypercholesterolemia, but that affects about 0.5% of people. The other 99.5% of us are not genetically fated to high LDL.

We forget that food itself affects both how much LDL we produce and how well our receptors clear it. The Portfolio study showed that a strict vegan diet rich in fiber, antioxidants, omega-3 fats, and plant sterols can lower LDL by around 30% in two weeks. We've documented similar responses within 30 days, in some people, simply by delivering those same four nutrients within a normal diet, no strict vegan regimen required. In our own randomized controlled trial, conducted with Mayo Clinic and the University of Manitoba, the average LDL drop was 9% in 30 days, with individual responses as high as 37.6%, and with 80% of participants lowering their LDL to some extent.

None of this is an argument against medication. Drugs have a real role, and I prescribe them. Lipfendra is a welcome new option, especially for people who'd benefit from PCSK9 inhibition but have avoided the medication class because of the needle. But, in the end, the drug manages a number. It doesn't address the reason the number was high. And unless you deal with the root cause, you can never hope to cure anything. You can only medicate and medicate and medicate some more.

If you're new to this site and found this useful, I write one of these evidence-based articles every week. You can get them in your inbox by joining my email list at the bottom of this page. No spam, no requirement to buy anything, just practical knowledge.